AUERBACH ALAN H sold $364K of PBYI
AUERBACH ALAN H (President and CEO) sold 44,058 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $8.26 ($0.36M total) on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s open-market sale under a 10b5-1 plan is new information, but it is generally less informative about near-term fundamentals than unscheduled selling.
Market read
Traders may briefly reassess sentiment around PBYI due to insider selling, but the 10b5-1 structure limits fundamental inference.
What to watch
The article does not disclose whether there were concurrent buys, option exercises, or other insider transactions around the same period, which could contextualize net insider behavior.
Background
The article is an SEC Form 4 insider transaction disclosure for PUMA Biotechnology, Inc. (PBYI).
Ticker impact
SEC Form 4 shows CEO Alan H. Auerbach sold 44,058 shares of PUMA Biotechnology at $8.2630 on 2026-07-06 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other disclosures.
The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider activity.
None.
None.
Counterpoint
Because the sale is on a 10b5-1 plan, it may be mechanically scheduled and not a bearish signal; traders may overreact to the headline.
Key entities
- issuerPUMA BIOTECHNOLOGY, INC.
Company whose CEO insider sale is disclosed via SEC Form 4.
- insiderAUERBACH ALAN H
President and CEO, reported an open-market sale of 44,058 shares under a 10b5-1 plan.
